TRNS vs. TXG, EYPT, ALNT, LAB, CTKB, AEHR, QSI, QTRX, SENS, and MASS
Should you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Transcat vs. Its Competitors
Transcat (NASDAQ:TRNS) and 10x Genomics (NASDAQ:TXG) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.
Transcat currently has a consensus price target of $114.00, suggesting a potential upside of 32.02%. 10x Genomics has a consensus price target of $14.96, suggesting a potential upside of 25.52%. Given Transcat's stronger consensus rating and higher probable upside, equities research analysts clearly believe Transcat is more favorable than 10x Genomics.
Transcat has a net margin of 5.21% compared to 10x Genomics' net margin of -25.14%. Transcat's return on equity of 6.47% beat 10x Genomics' return on equity.
In the previous week, 10x Genomics had 4 more articles in the media than Transcat. MarketBeat recorded 4 mentions for 10x Genomics and 0 mentions for Transcat. 10x Genomics' average media sentiment score of 1.57 beat Transcat's score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media.
98.3% of Transcat shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 2.3% of Transcat shares are owned by insiders. Comparatively, 10.0% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Transcat has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Transcat has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.
Summary
Transcat beats 10x Genomics on 10 of the 16 factors compared between the two stocks.
Get Transcat News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transcat Competitors List
Related Companies and Tools
This page (NASDAQ:TRNS) was last updated on 7/7/2025 by MarketBeat.com Staff
Free TRNS Stock Alerts